Literature DB >> 35073860

Correction to: Molecular identification and antifungal susceptibility profile of yeast from vulvovaginal candidiasis.

Yu Shi1,2,3, Yuxia Zhu1,2, Shangrong Fan4,5,6, Xiaoping Liu7, Yiheng Liang1,2, Yingying Shan1,2.   

Abstract

Entities:  

Year:  2022        PMID: 35073860      PMCID: PMC8785548          DOI: 10.1186/s12879-021-06601-x

Source DB:  PubMed          Journal:  BMC Infect Dis        ISSN: 1471-2334            Impact factor:   3.090


× No keyword cloud information.

Correction to: BMC Infectious Diseases (2020) 20:287 10.1186/s12879-020-04985-w

Following publication of the original article [1], the authors identified an error in Table 3. The correct table (Table 3) is given in this erratum and the original article has been corrected.
Table 3

In vitro antifungal susceptibility of 1844 clinical isolates of Candida species as determined by the CLSI method

Candida species (n)Antifungal agents
BUCCLOFLCITCMICTECVRC
C. lusitaniae, n = 1Range0.030.030.1250.030.030.030.03
C. Fabianii, n = 3Range0.03–0.250.03–0.060.5–10.03–0.250.125–10.030.03
MIC500.1250.030.50.060.1250.030.03
MIC900.250.0610.2510.030.03
Trichosporon asahii, n = 1Range0.030.030.250.030.060.030.03
Rhodotorula, n = 3Range0.03–0.50.03–14–1280.03–80.25–80.03–0.50.03–1
MIC500.060.0664210.060.03
MIC900.51128880.51
Kodamaea ohmeri, n = 2Range0.125–0.50.030.25–20.125–0.250.25–0.50.030.03
MIC500.1250.030.250.1250.250.030.03
MIC900.50.0320.250.50.030.03
Issatchenkia terricola, n = 2Range1–40.06–0.12532–640.25–0.50.50.250.25
MIC5010.06320.250.50.250.25
MIC9040.125640.50.50.250.25
Torulaspora pretoriensis, n = 1Range0.250.0380.50.50.1250.125
ATCC90028*Range0.015–0.50.015–0.50.125–20.015–40.008–0.0150.015–320.015–8
GM0.040.030.210.080.060.030.03
MIC900.1250.030.50.250.0150.030.03

GM geometry mean, BUC butoconazole, CLO Clotrimazole, FLC Fluconazole, ITC Itraconazole, VRC Voriconazole, MIC Miconazole, TEC Terconazole, AmB Amphotericin B, FLU Flucytosine, NYS Nystatin, TEB Terbinafine, AFG Anidulafungin, CFG Caspofungin, MFG Micafungin

aATCC90028 was tested 57 times

In vitro antifungal susceptibility of 1844 clinical isolates of Candida species as determined by the CLSI method C. albicans n = 1272 C. africana n = 49 C. dubliniensis n = 1 C. glabrata n = 267 C. nivariensis n = 9 C. bracarensis n = 2 C. parapsilosis n = 76 C. metapsilosis n = 20 C. orthopsilosis n = 6 C. tropicalis n = 61 C. krusei n = 54 Saccharomyces cerevisiae n = 12 C. guilliermondii n = 2 C. lusitaniae n = 1 C. fabianii n = 3 Trichosporon asahii n = 1 Rhodotorula n = 3 Kodamaea ohmeri n = 2 Issatchenkia terricola n = 2 Torulaspora pretoriensis n = 1 GM geometry mean, BUC butoconazole, CLO Clotrimazole, FLC Fluconazole, ITC Itraconazole, VRC Voriconazole, MIC Miconazole, TEC Terconazole, AmB Amphotericin B, FLU Flucytosine, NYS Nystatin, TEB Terbinafine, AFG Anidulafungin, CFG Caspofungin, MFG Micafungin aATCC90028 was tested 57 times
  1 in total

1.  Molecular identification and antifungal susceptibility profile of yeast from vulvovaginal candidiasis.

Authors:  Yu Shi; Yuxia Zhu; Shangrong Fan; Xiaoping Liu; Yiheng Liang; Yingying Shan
Journal:  BMC Infect Dis       Date:  2020-04-19       Impact factor: 3.090

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.